

- 11:00 a.m. Briefing on Investigative Matters (Closed—Ex. 5 & 6)
 2:00 p.m. Meeting with Commonwealth Edison (Public Meeting) (Contact: Bob Capra—301-415-1395)

Wednesday, November 5

- 9:30 a.m. Briefing on Proposed Resolution to a Petition for Rulemaking Relating to Use of Potassium Iodide (KI) following Severe Accident at a Nuclear Power Plant (Public Meeting)
 11:00 a.m. Affirmation Session (Public Meeting)

(Please Note: These items will be affirmed immediately following the conclusion of the preceding meeting)

- a. Final Amendments to 10 CFR Part 73, "Changes to Nuclear Power Plants Security Requirements"
 b. Final rule on Exempt Distribution and Use of a Radioactive Drug Containing One Microcurie of Carbon 14 Urea (Parts 30 and 32)

Week of November 31—Tentative

There are no meetings the week of November 10.

Week of November 17—Tentative

Friday, November 21

- 11:30 a.m. Affirmation Session (Public Meeting) (if needed)

Week of November 24—Tentative

There are no meetings the week of November 24.

ADDITIONAL INFORMATION: The Commission meeting, "Briefing on Staff's Plans for 50.59 Regulatory Process Improvements," previously scheduled on Wednesday, November 5, has been postponed. The rescheduled date for the meeting has not been set.

The schedule for Commission meetings is subject to change on short notice. To verify the status of meetings call (Recording)—(301) 415-1292.

CONTACT PERSON FOR MORE INFORMATION: Bill Hill (301) 415-1661.

The NRC Commission Meeting Schedule can be found on the Internet at: <http://www.nrc.gov/SECY/smj/schedule.htm>

This notice is distributed by mail to several hundred subscribers: if you no longer wish to receive it, or would like to be added to it, please contact the Office of the Secretary, Attn: Operations Branch, Washington, D.C. 20555 (301-415-1661).

In addition, distribution of this meeting notice over the Internet system is available. If you are interested in receiving this Commission meeting schedule electronically, please send an

electronic message to wmh@nrc.gov or dkw@nrc.gov.

Dated: October 29, 1997.

William M. Hill, Jr.,
Secretary Tracking Officer, Office of the Secretary.

[FR Doc. 97-29135 Filed 10-30-97; 12:24 p.m.]

[BILLING CODE 7590-01-M]

NUCLEAR REGULATORY COMMISSION

Workshop Notice To Solicit Public Comments on Draft Regulatory Guide and Standard Review Plan Section for Risk-Informed Inservice Inspection Programs for Piping at Nuclear Power Plants

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of change in date for workshop.

SUMMARY: The **Federal Register** notice, dated October 15, 1997 (Volume 62, Number 199, page 53663) announced the availability and solicited public comment on drafts of a regulatory guide and a Standard Review Plan Section for risk-informed inservice inspection programs for piping. These issuances follow the Commission's August 16, 1995 (60 FR 42622) policy statement on the "Use of PRA Methods in Nuclear Regulatory Activities." In June 1997, the NRC published for public comment (62 FR 34321) four draft guides, three standard review plans and a NUREG series document on the use of PRA in nuclear power reactor licensing. The NRC is developing guidance for power reactor licensees on acceptable methods for using probabilistic risk assessment (PRA) information and insights in support of plant-specific applications to change the current licensing basis (CLB) for inservice inspection of piping, known as risk-informed inservice inspection (RI-ISI) programs. The use of such PRA information and guidance will be voluntary. To facilitate comment, the Commission will conduct a workshop to explain the draft documents and answer questions. **DATES:** The workshop will be held on November 20-21, 1997 (not on November 19th, as announced in the October 15, 1997, **Federal Register**).

Registration

There is no registration fee for this workshop. However, we request that interested parties register in writing to Kesselman-Jones, 8912 James Ave., NE., Albuquerque, NM 87111, their intent on participating in the workshop. Please

include name, organization, address and phone number with your registration request. Notification of attendance (e.g., pre-registration) is requested so that adequate space, etc., for the workshop can be arranged. Questions regarding meeting registration or fees should be directed to Kesselman-Jones, phone (505) 271-0003, fax (505) 271-0482, e-mail kessjones@aol.com.

Onsite registration begins on November 19 at 3:00 P.M. The comment period expires on January 13, 1997. Comments received after this date will be considered if it is practical to do so, but the Commission is able to assure consideration only for comments received on or before this date. See the October 15, 1997 Notice for additional details.

Implementation

It is intended that the risk-informed regulatory guide on inservice inspection of piping (DG-1063), and its associated Standard Review Plan Section 3.9.8, be published by early to mid CY 1998.

Dated at Rockville, Maryland, this 29th day of October 1997.

For the Nuclear Regulatory Commission.

Mark A. Cunningham,
Chief, Probabilistic Risk Analysis Branch, Division of Systems Technology, Office of Nuclear Regulatory Research.

[FR Doc. 97-28989 Filed 10-31-97; 8:45 am]

BILLING CODE 7590-01-P

NUCLEAR REGULATORY COMMISSION

NRC/Nuclear Pharmacy and Radiopharmaceutical Manufacturer Industry—Public Workshop on the Public Comments on Draft Regulatory Guides DG-0006 and DG-0007

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: Notice of meeting.

SUMMARY: The U.S. Nuclear Regulatory Commission will be holding a public meeting to discuss the public comments received on two draft regulatory guides: Draft Regulatory Guide DG-0006, "Guide for the Preparation of Applications for Commercial Nuclear Pharmacy Licenses," and Draft Regulatory Guide DG-0007, "Guide for the Preparation of Applications for Licenses to Authorize Distribution of Various Items to Commercial Nuclear Pharmacies and Medical Use Licensees." These documents provide guidance to individuals applying for commercial nuclear pharmacy and radiopharmaceutical manufacturer distribution licenses. Representatives of